β-Blocker prescription and outcomes in hemodialysis patients from the japan dialysis outcomes and practice patterns study

Kazushi Nakao, Hirofumi Makino, Satoshi Morita, Yoshimitsu Takahashi, Tadao Akizawa, Akira Saito, Yasushi Asano, Kiyoshi Kurokawa, Shunichi Fukuhara, Takashi Akiba

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background/Aims: Given the clear benefits of mortality reduction observed for most β-blockers in clinical trials, they are relatively underused in hemodialysis patients. Since the outcomes associated with the use of β-blockers are not fully known, we investigated their effect on mortality among a cohort of hemodialysis patients. Methods: Data were analyzed from the Dialysis Outcomes and Practice Patterns Study phase II for 2,286 randomly selected patients on hemodialysis in Japan. Treatment with β-blockers was the major predictor variable. The main outcome measure was all-cause mortality. Cox regression analysis was used to assess an association between treatment with β-blockers and the risk of death. Results: 247 patients (11.9%) were administered β-blockers and 1,828 patients (88.1%) were not. Whereas patients treated with β-blockers had a higher prevalence of hypertension and coronary heart disease, Kaplan-Meier analysis revealed that all-cause mortality rates were significantly (p < 0.007) decreased in patients treated with β-blockers compared to those without. In multivariable, fully adjusted models, treatment with β-blockers was also independently associated with reduced all-cause mortality (hazard ratio = 0.48; p = 0.02). Conclusion: This study indicated a possible association between the use of β-blockers and reduced risk of mortality in hemodialysis patients. These results should be confirmed in further randomized controlled trials.

Original languageEnglish
JournalNephron - Clinical Practice
Volume113
Issue number3
DOIs
Publication statusPublished - Oct 1 2009

Fingerprint

Prescriptions
Renal Dialysis
Dialysis
Japan
Mortality
Kaplan-Meier Estimate
Coronary Disease
Therapeutics
Randomized Controlled Trials
Regression Analysis
Outcome Assessment (Health Care)
Clinical Trials
Hypertension

Keywords

  • β-Blockers
  • All-cause mortality
  • Dialysis Outcomes and Practice Patterns Study
  • Hemodialysis

ASJC Scopus subject areas

  • Nephrology

Cite this

β-Blocker prescription and outcomes in hemodialysis patients from the japan dialysis outcomes and practice patterns study. / Nakao, Kazushi; Makino, Hirofumi; Morita, Satoshi; Takahashi, Yoshimitsu; Akizawa, Tadao; Saito, Akira; Asano, Yasushi; Kurokawa, Kiyoshi; Fukuhara, Shunichi; Akiba, Takashi.

In: Nephron - Clinical Practice, Vol. 113, No. 3, 01.10.2009.

Research output: Contribution to journalArticle

Nakao, K, Makino, H, Morita, S, Takahashi, Y, Akizawa, T, Saito, A, Asano, Y, Kurokawa, K, Fukuhara, S & Akiba, T 2009, 'β-Blocker prescription and outcomes in hemodialysis patients from the japan dialysis outcomes and practice patterns study', Nephron - Clinical Practice, vol. 113, no. 3. https://doi.org/10.1159/000232593
Nakao, Kazushi ; Makino, Hirofumi ; Morita, Satoshi ; Takahashi, Yoshimitsu ; Akizawa, Tadao ; Saito, Akira ; Asano, Yasushi ; Kurokawa, Kiyoshi ; Fukuhara, Shunichi ; Akiba, Takashi. / β-Blocker prescription and outcomes in hemodialysis patients from the japan dialysis outcomes and practice patterns study. In: Nephron - Clinical Practice. 2009 ; Vol. 113, No. 3.
@article{4133ca5d206540ca9c3bb367a80bc76f,
title = "β-Blocker prescription and outcomes in hemodialysis patients from the japan dialysis outcomes and practice patterns study",
abstract = "Background/Aims: Given the clear benefits of mortality reduction observed for most β-blockers in clinical trials, they are relatively underused in hemodialysis patients. Since the outcomes associated with the use of β-blockers are not fully known, we investigated their effect on mortality among a cohort of hemodialysis patients. Methods: Data were analyzed from the Dialysis Outcomes and Practice Patterns Study phase II for 2,286 randomly selected patients on hemodialysis in Japan. Treatment with β-blockers was the major predictor variable. The main outcome measure was all-cause mortality. Cox regression analysis was used to assess an association between treatment with β-blockers and the risk of death. Results: 247 patients (11.9{\%}) were administered β-blockers and 1,828 patients (88.1{\%}) were not. Whereas patients treated with β-blockers had a higher prevalence of hypertension and coronary heart disease, Kaplan-Meier analysis revealed that all-cause mortality rates were significantly (p < 0.007) decreased in patients treated with β-blockers compared to those without. In multivariable, fully adjusted models, treatment with β-blockers was also independently associated with reduced all-cause mortality (hazard ratio = 0.48; p = 0.02). Conclusion: This study indicated a possible association between the use of β-blockers and reduced risk of mortality in hemodialysis patients. These results should be confirmed in further randomized controlled trials.",
keywords = "β-Blockers, All-cause mortality, Dialysis Outcomes and Practice Patterns Study, Hemodialysis",
author = "Kazushi Nakao and Hirofumi Makino and Satoshi Morita and Yoshimitsu Takahashi and Tadao Akizawa and Akira Saito and Yasushi Asano and Kiyoshi Kurokawa and Shunichi Fukuhara and Takashi Akiba",
year = "2009",
month = "10",
day = "1",
doi = "10.1159/000232593",
language = "English",
volume = "113",
journal = "Nephron - Experimental Nephrology",
issn = "1660-8151",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - β-Blocker prescription and outcomes in hemodialysis patients from the japan dialysis outcomes and practice patterns study

AU - Nakao, Kazushi

AU - Makino, Hirofumi

AU - Morita, Satoshi

AU - Takahashi, Yoshimitsu

AU - Akizawa, Tadao

AU - Saito, Akira

AU - Asano, Yasushi

AU - Kurokawa, Kiyoshi

AU - Fukuhara, Shunichi

AU - Akiba, Takashi

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Background/Aims: Given the clear benefits of mortality reduction observed for most β-blockers in clinical trials, they are relatively underused in hemodialysis patients. Since the outcomes associated with the use of β-blockers are not fully known, we investigated their effect on mortality among a cohort of hemodialysis patients. Methods: Data were analyzed from the Dialysis Outcomes and Practice Patterns Study phase II for 2,286 randomly selected patients on hemodialysis in Japan. Treatment with β-blockers was the major predictor variable. The main outcome measure was all-cause mortality. Cox regression analysis was used to assess an association between treatment with β-blockers and the risk of death. Results: 247 patients (11.9%) were administered β-blockers and 1,828 patients (88.1%) were not. Whereas patients treated with β-blockers had a higher prevalence of hypertension and coronary heart disease, Kaplan-Meier analysis revealed that all-cause mortality rates were significantly (p < 0.007) decreased in patients treated with β-blockers compared to those without. In multivariable, fully adjusted models, treatment with β-blockers was also independently associated with reduced all-cause mortality (hazard ratio = 0.48; p = 0.02). Conclusion: This study indicated a possible association between the use of β-blockers and reduced risk of mortality in hemodialysis patients. These results should be confirmed in further randomized controlled trials.

AB - Background/Aims: Given the clear benefits of mortality reduction observed for most β-blockers in clinical trials, they are relatively underused in hemodialysis patients. Since the outcomes associated with the use of β-blockers are not fully known, we investigated their effect on mortality among a cohort of hemodialysis patients. Methods: Data were analyzed from the Dialysis Outcomes and Practice Patterns Study phase II for 2,286 randomly selected patients on hemodialysis in Japan. Treatment with β-blockers was the major predictor variable. The main outcome measure was all-cause mortality. Cox regression analysis was used to assess an association between treatment with β-blockers and the risk of death. Results: 247 patients (11.9%) were administered β-blockers and 1,828 patients (88.1%) were not. Whereas patients treated with β-blockers had a higher prevalence of hypertension and coronary heart disease, Kaplan-Meier analysis revealed that all-cause mortality rates were significantly (p < 0.007) decreased in patients treated with β-blockers compared to those without. In multivariable, fully adjusted models, treatment with β-blockers was also independently associated with reduced all-cause mortality (hazard ratio = 0.48; p = 0.02). Conclusion: This study indicated a possible association between the use of β-blockers and reduced risk of mortality in hemodialysis patients. These results should be confirmed in further randomized controlled trials.

KW - β-Blockers

KW - All-cause mortality

KW - Dialysis Outcomes and Practice Patterns Study

KW - Hemodialysis

UR - http://www.scopus.com/inward/record.url?scp=68349085669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349085669&partnerID=8YFLogxK

U2 - 10.1159/000232593

DO - 10.1159/000232593

M3 - Article

C2 - 19672110

AN - SCOPUS:68349085669

VL - 113

JO - Nephron - Experimental Nephrology

JF - Nephron - Experimental Nephrology

SN - 1660-8151

IS - 3

ER -